Sangamo Therapeutics, Inc
ST-920
Fabry disease
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on ST-920 for Fabry disease is in focus around Date TBD.
Primary source
· SEC 8-K
verified 14h ago
“The FDA has recently affirmed to us that two-year eGFR data may serve as confirmatory evidence for traditional approval.”